Nicola Fattorelli

Nicola Fattorelli

Auto-generated profile, based on publicly available information

Nicola Fattorelli

Centre for Brain and Disease Research, Flanders Institute for Biotechnology (VIB), Leuven, Belgium

Research Focus & Metrics

Academic Career Length

8Years (2019-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
1 April 2019 in Cell Reports
Verified
Journal Article
Open access
CFCarlo Sala Frigerio
Carlo Sala Frigerio
LWLeen Wolfs
Leen Wolfs
NFNicola Fattorelli
Nicola Fattorelli
NTNicola Thrupp
Nicola Thrupp
IVIryna Voytyuk
Iryna Voytyuk
BSBart De Strooper
Bart De Strooper
Gene expression profiles of more than 10,000 individual microglial cells isolated from cortex and hippocampus of male and female AppNL-G-F mice over time demonstrate that progressive amyloid-β accumulation accelerates two main activated microglia states that are also present during normal aging. Activated response microglia (ARMs) are composed of specialized subgroups overexpressing MHC type II and putative tissue repair genes (Dkk2, Gpnmb, and Spp1) and are strongly enriched with Alzheimer's disease (AD) risk genes. Microglia from female mice progress faster in this activation trajectory. Similar activated states are also found in a second AD model and in human brain. Apoe, the major genetic risk factor for AD, regulates the ARMs but not the interferon response microglia (IRMs). Thus, the ARMs response is the converging point for aging, sex, and genetic AD risk factors.

1 September 2020 in Cell Reports
Verified
Journal Article
Open access
NTNicola Thrupp
Nicola Thrupp
CFCarlo Sala Frigerio
Carlo Sala Frigerio
LWLeen Wolfs
Leen Wolfs
NSNathan G. Skene
Nathan G. Skene
NFNicola Fattorelli
Nicola Fattorelli
MFMark Fiers
Mark Fiers
Single-nucleus RNA sequencing (snRNA-seq) is used as an alternative to single-cell RNA-seq, as it allows transcriptomic profiling of frozen tissue. However, it is unclear whether snRNA-seq is able to detect cellular state in human tissue. Indeed, snRNA-seq analyses of human brain samples have failed to detect a consistent microglial activation signature in Alzheimer’s disease. Our comparison of microglia from single cells and single nuclei of four human subjects reveals that, although most genes show similar relative abundances in cells and nuclei, a small population of genes (∼1%) is depleted in nuclei compared to whole cells. This population is enriched for genes previously implicated in microglial activation, including APOE, CST3, SPP1, and CD74, comprising 18% of previously identified microglial-disease-associated genes. Given the low sensitivity of snRNA-seq to detect many activation genes, we conclude that snRNA-seq is not suited for detecting cellular activation in microglia in human disease.

28 October 2019 in Nature Neuroscience
Verified
Journal Article
Closed access
PDF file
RMRenzo Mancuso
Renzo Mancuso
JDJohanna Van Den Daele
Johanna Van Den Daele
NFNicola Fattorelli
Nicola Fattorelli
LWLeen Wolfs
Leen Wolfs
SBSriram Balusu
Sriram Balusu
BSBart De Strooper
Bart De Strooper

17 January 2020 in EMBO Molecular Medicine
Verified
Journal Article
Open access
PDF file
ASAnnerieke Sierksma
Annerieke Sierksma
ALAshley Lu
Ashley Lu
RMRenzo Mancuso
Renzo Mancuso
NFNicola Fattorelli
Nicola Fattorelli
NTNicola Thrupp
Nicola Thrupp
MFMark Fiers
Mark Fiers
Polygenic risk scores have identified that genetic variants without genome‐wide significance still add to the genetic risk of developing Alzheimer's disease (AD). Whether and how subthreshold risk loci translate into relevant disease pathways is unknown. We investigate here the involvement of AD risk variants in the transcriptional responses of two mouse models: APPswe/PS1 L166P and Thy‐TAU22. A unique gene expression module, highly enriched for AD risk genes, is specifically responsive to Aβ but not TAU pathology. We identify in this module 7 established AD risk genes ( APOE , CLU , INPP5D , CD33, PLCG2 , SPI1, and FCER1G ) and 11 AD GWAS genes below the genome‐wide significance threshold ( GPC2, TREML2, SYK, GRN, SLC2A5, SAMSN1, PYDC1, HEXB, RRBP1, LYN, and BLNK), that become significantly upregulated when exposed to Aβ. Single microglia sequencing confirms that Aβ, not TAU, pathology induces marked transcriptional changes in microglia, including increased proportions of activated microglia. We conclude that genetic risk of AD functionally translates into different microglia pathway responses to Aβ pathology, placing AD genetic risk downstream of the amyloid pathway but upstream of TAU pathology.

11 January 2021 in Nature Protocols
Verified
Journal Article
Closed access
PDF file
NFNicola Fattorelli
Nicola Fattorelli
AMAnna Martinez-Muriana
Anna Martinez-Muriana
LWLeen Wolfs
Leen Wolfs
IGIvana Geric
Ivana Geric
BSBart De Strooper
Bart De Strooper
RMRenzo Mancuso
Renzo Mancuso

16 September 2025 in Nature Metabolism
Verified
Journal Article
Open access
PDF file
FRFrancesca Rizzollo
Francesca Rizzollo
AEAbril Escamilla-Ayala
Abril Escamilla-Ayala
NFNicola Fattorelli
Nicola Fattorelli
NLNatalia Barbara Lysiak
Natalia Barbara Lysiak
SMSanket More
Sanket More
PAPatrizia Agostinis
Patrizia Agostinis
Iron sustains cancer cell plasticity, yet it also sensitizes the mesenchymal, drug-tolerant phenotype to ferroptosis. This posits that iron compartmentalization must be tightly regulated. However, the molecular machinery governing organelle Fe(II) compartmentalization remains elusive. Here, we show that BDH2 is a key effector of inter-organelle Fe(II) redistribution and ferroptosis vulnerability during melanoma transition from a melanocytic (MEL) to a mesenchymal-like (MES) phenotype. In MEL cells, BDH2 localizes at the mitochondria–lysosome contacts (MLCs) to generate the siderophore 2,5-dihydroxybenzoic acid (2,5-DHBA), which ferries iron into the mitochondria. Fe(II) transfer by BDH2 supports mitochondrial bioenergetics, which is required to maintain lysosomal acidification and MLC formation. Loss of BDH2 alters lysosomal pH and MLC tethering dynamics, causing lysosomal iron sequestration, which primes MES cells for ferroptosis. Rescuing BDH2 expression, or supplementing 2,5-DHBA, rectifies lysosomal pH and MLCs, protecting MES cells from ferroptosis and enhancing their ability to metastasize. Thus, we unveil a BDH2-dependent mechanism that orchestrates inter-organelle Fe(II) transfer, linking metabolic regulation of lysosomal pH to the ferroptosis vulnerability of the mesenchymal, drug-tolerant cancer cells.